Mouse IL-17A, His Tag (Cat. No. CT8-M5240) stimulates secretion of IL-6 by NIH-3T3 cells. The ED50 for this effect is 2.132-5.005 ng/mL.
Loaded Human IL-17 RA, Fc Tag (Cat. No. ILA-H5257) on Protein A Biosensor, can bind Mouse IL-17A, His Tag (Cat. No. CT8-M5240) with an affinity constant of 20.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-C5249 | Cynomolgus | Cynomolgus IL-17A / CTLA-8 Protein, His Tag |  |
||
| ILA-H82Q1 | Human | Biotinylated Human IL-17A / CTLA-8 Protein, His,Avitag™ |  |
|
|
| CT8-M5240 | Mouse | Mouse IL-17A / CTLA-8 Protein, His Tag (MALS verified) |  |
|
|
| ILA-H5118 | Human | Human IL-17A / CTLA-8 Protein, Tag Free (MALS verified) |  |
|
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Virulizin | Approved | Aptose, Symbion Health, Zor Pharmaceuticals | Gastric cancer, Colorectal cancer, Renal carcinoma, Cervical carcinoma, Kaposi's sarcoma, Pancreatic cancer, Melanoma | Details | ||||||
| Ixekizumab | LY-2439821, LY2439821 | Approved | Lilly | TALTZ | fda | Plaque psoriasis | ELI LILLY AND CO | 2016-03-22 | Psoriatic erythroderma, Ankylosing Spondylitis (AS), Plaque psoriasis, Pustular psoriasis, Psoriatic arthritis, Psoriasis vulgaris | Details |
| Secukinumab | AIN-457; KB-03303A; NVP-AIN-457 | Approved | Novartis, Maruho Pharmaceutical | Secukinumab | 日本 | Psoriasis vulgaris, Psoriatic arthritis | 诺华,Maruho Pharmaceutical | 2014-12-26 00:00:00.0 | Plaque psoriasis, Ankylosing Spondylitis (AS), Pustular psoriasis, Psoriasis, Psoriatic arthritis, Psoriasis vulgaris | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Tibulizumab (Eli Lilly) | Phase Ⅰ | Lilly | Sjoegren's syndrome | Details | |
| ALX-0761 | ALX-0761; M-1095; MSB-0010841 | Phase Ⅱ | Ablynx, Merck Serono | Psoriasis | Details |
| GR-1501 | GR-1501,GR1501; GR 1501 | Phase Ⅰ | Chongqing Genrix Biopharmaceutical, Genrix (Shanghai) Biopharmaceutical | Spondyloarthritis, Plaque psoriasis | Details |
| JNJ-63823539 | JNJ-63823539 | Phase Ⅰ | Janssen | Rheumatoid arthritis (RA) | Details |
| RO-7040547 | BIT-7201A; RG-7990; RO-7040547 | Phase Ⅰ | Genentech | Allergic asthma | Details |
| Vidofludimus | 4SC-101; SC-12267,4SC101,SC12267 | Phase Ⅱ | 4SC AG | Ulcerative colitis, Crohn's disease | Details |
| Recombinant humanized anti-IL17A monoclonal antibody(Shanghai CP Guojian) | 608 | Phase Ⅰ | Shanghai CP Guojian | Plaque psoriasis | Details |
| Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | Phase Ⅰ | Livzon Pharmaceutical Group, Beijing Xinkanghe Biomedical Technology Co., Ltd. | Plaque psoriasis | Details | |
| Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai Junshi Biosciences) | JS005 | Phase Ⅰ | Shanghai Junshi Biosciences | Plaque psoriasis, Psoriasis, Rheumatoid arthritis (RA) | Details |
| COVA-322 | COVA-322 | Phase Ⅱ | Covagen | Plaque psoriasis | Details |
| UCB-0159 | UCB-0159 | Phase Ⅰ | UCB | Autoimmune diseases | Details |
| Vunakizumab | SHR-1314 | Phase Ⅱ | Jiangsu Hengrui Medicine | Spondyloarthritis, Plaque psoriasis | Details |
| ABY-035 | ABY-035; AFB-035 | Phase Ⅰ | Affibody | Psoriasis | Details |
| Recombinant anti-IL-17A humanized monoclonal antibody (Shanghai CP Guojian) | Phase Ⅰ | Shanghai CP Guojian | Plaque psoriasis | Details | |
| SCH-900117 | SCH-900117; SCH900117 | Phase Ⅰ | Merck Sharp & Dohme | Rheumatoid arthritis (RA) | Details |
| CJM-112 | CJM-112 | Phase Ⅱ | Novartis | Plaque psoriasis, Hidradenitis suppurativa, Multiple sclerosis (MS) | Details |
This web search service is supported by Google Inc.
A-Z
